

Supplementary Table 1. The difference in RAB13 expression between non-GCB DLBCL and Normal Lymph nodes

	RAB13		Total	<i>P</i> value
	Positive (%)	Negative (%)		
DLBCL (non-GCB)	32 (40)	48 (60)	80	<0.05
Normal lymph nodes	3 (15)	17 (85)	20	

DLBCL: diffuse large B-cell lymphoma

Supplementary Table 2. Associations of RAB13 expression with clinicopathological factors in DLBCL


Characteristics	RAB13		χ^2	<i>P</i> value
	Positive [N (%)]	Negative [N (%)]		
Sex				0.4100
Male	13 (35.14)	24 (64.86)	0.6788	
Female	19 (44.18)	24 (55.81)		
Age				0.5780
<60	12 (36.37)	21 (63.63)	0.3095	
≥60	20 (42.56)	27 (57.44)		
Lugano stage				0.0058
I–II	8 (22.86)	27 (77.14)	7.619	
III–IV	24 (53.33)	21 (46.67)		
International Prognostic Index				0.0175

Low (0–2)	10 (26.32)	(73.68)	28	5.647	
High (3–5)	22 (52.38)	(47.62)	20		
Extranodal involvements					0.0006
≤1	11 (23.91)	(76.09)	35	11.67	
>1	21 (61.76)	(38.24)	13		
LDH					0.0039
Normal	13 (27.08)	(72.92)	35	8.342	
High	19 (59.38)	(40.63)	13		
Therapeutic evaluation					0.0019
CR + PR	10 (19.05)	(80.95)	32	9.657	
R/R	22 (63.16)	(36.84)	16		


Supplementary Table 3. The relationship between RAB13 expression and response to Lenalidomide Maintenance Therapy

	RAB13		Total	<i>P</i> value
	Positive [N (%)]	Negative [N (%)]		
R/R	16 (72.73)	6 (27.27)	22	<i>P</i> = 0.0127
CR + PR	6 (33.33)	12 (66.67)	18	


Supplementary Figure 1




Supplementary Figure 2




Supplementary Figure 3





Supplementary Figure 5




Supplementary Figure 6

SU-DHL-2

OE

NC



Supplementary Figure 7

